Alan Fournier (Trades, Portfolio) is the founder and managing member of Pennant Capital Management, a long/short hedge fund. Today, the hedge is composed of 40 stocks, and 6 have been bought during the last quarter. The total value of the portfolio is $5,338 million with 16% Q/Q Turnover.
According to GuruFocus' All-In-One screener, the following are stocks that the investor traded (increased his stake or bought shares for the first time) whose price is having the highest performance.
SunEdison Inc (SUNE)
During the Q1 2015 he bought 2,111,535 shares of SUNE and since then, the stock has risen by 32.2%.
SUNE has a market cap of $8.74 billion and an enterprise value of $18.36 billion. The Company is engaged in the manufacture and sale of wafers and related products to the semiconductor and solar industries. The Company is engaged in two reportable industry segments: Semiconductor Materials and Solar Energy.
The price of the stock has risen by 212% during the last 5 years, 60% since the beginning of the year and 35% during the last 12 months. The stock is now -3.43% from its 52-week high and +141.13% from its 52-week low.
The company has a profitability and growth ratio of 5/10 with deep negative returns (ROE -653.53%, ROA -9.18%).
David Einhorn is the main guru holding SUNE with 24,953,888 shares, ammounting to 9.09% of shares outstanding, or 7.83% of total assets of his portfolio. Alan Fournier (Trades, Portfolio) holds 0.77% of outstanding shares that is the 0.95% of his total assets.
Broadcom Corp (BRCM)
During the Q1 2015 he increased his stake of BRCM by 2.08% and since then, the stock has risen by 21.80%.
BRCM has a market cap of $31.6 billion and an enterprise value of $30.25 billion. The Company is provider of semiconductors for wired and wireless communications. It provides a portfolio of SoCs that seamlessly deliver voice, video, data and multimedia connectivity in the home, office and mobile environments. Its business segments include Broadband and Connectivity, and Infrastructure and Networking.
The price of the stock has risen by 47% during the last 5 years, 23% since the beginning of the year and 38% during the last 12 months. The stock is now -8.44% from its 52-week high and +53.13% from its 52-week low.
The company has a profitability and growth ratio of 7/10 with positive returns (ROE 7.92%, ROA 5.74%).
PRIMECAP Management (Trades, Portfolio)Â is the main guru holding BRCM with 3,453,700 shares, ammounting to 0.58% of shares outstanding, or 0.15% of total assets of his portfolio. Alan Fournier (Trades, Portfolio) holds a very easy stake with 0.08% of outstanding shares.
Realogy Holdings Corp (RLGY)
During Q1 2015 he bought 2,698,946 shares of RLGY and since then, the stock has risen by 6.1%.
RLGY has a market cap of $7.07 billion and an enterprise value of $10.8 billion. The Company is a franchisor of residential real estate brokerages in the real estate industry. Its primary objective as the franchisor of residential real estate brokerages in the world are to sell new franchises, retain existing franchises, create or acquire new brands and, importantly, provide branding and support to franchisees.
The price of the stock has risen by 41% during the last 5 years, 9% since the beginning of the year and 28% during the last 12 months. The stock is now -2.74% from its 52-week high and +46.86% from its 52-week low.
The company has a profitability and growth ratio of 4/10 with positive returns (ROE 7.46%, ROA 2.11%) but negative growth rate over the last 3 years (Revenue -58% and EBITDA -62%).
Steve Mandel (Trades, Portfolio)Â is the main guru holding RLGY with 10,406,478 shares, ammounting to 7.1% of shares outstanding, or 1.79% of total assets of his portfolio. Alan Fournier (Trades, Portfolio) holds 1.84% of outstanding shares that is 2.3% of his total assets.
Impax Laboratories Inc (IPXL)
During Q1 2015 he increased his stake of IPXL by 279.85% and since then, the stock has risen by 3.5%.
IPXL has a market cap of $3.48 billion and an enterprise value of $3.74 billion. The Company is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as 'generics' in addition to the development and marketing of branded products.
The price of the stock has risen by 181% during the last 5 years, 53% since the beginning of the year and 37% during the last 12 months. The stock is now -4.71% from its 52-week high and +124.43% from its 52-week low.
The company has a profitability and growth rating of 6/10 with positive returns (ROE 5.11%, ROA 3.72%) and almost null growth rate over the last 3 years about revenue (+3.50%) and EBITDA (+1.60%).
Alan Fournier (Trades, Portfolio) is the is the main guru holding IPXL with 2,025,000 shares, ammounting to 2.82% of shares outstanding, or 1.78% of total assets of his portfolio, followed by NWQ Managers (Trades, Portfolio) with 1.31% of outstanding shares, and John Hussman (Trades, Portfolio) with 0.35%.
Summary:
| Ticker | Price growth since buy/increase in Q1 2015 | 5-year performance |
| SUNE | +32.20% | +212% |
| BRCM | +21.80% | +47% |
| RLGY | +6.10% | +41% |
| IPXL | +3.50% | +181% |
